147 related articles for article (PubMed ID: 34035370)
1. Efficacy, safety and tolerability of drugs studied in phase 3 randomized controlled trials in solid tumors over the last decade.
Ribnikar D; Goldvaser H; Veitch ZW; Ocana A; Templeton AJ; Šeruga B; Amir E
Sci Rep; 2021 May; 11(1):10843. PubMed ID: 34035370
[TBL] [Abstract][Full Text] [Related]
2. Associations between safety, tolerability, and toxicity and the reporting of health-related quality of life in phase III randomized trials in common solid tumors.
Saleh RR; Meti N; Ribnikar D; Goldvaser H; Ocana A; Templeton AJ; Seruga B; Amir E
Cancer Med; 2020 Nov; 9(21):7888-7895. PubMed ID: 32886422
[TBL] [Abstract][Full Text] [Related]
3. The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs.
Niraula S; Seruga B; Ocana A; Shao T; Goldstein R; Tannock IF; Amir E
J Clin Oncol; 2012 Aug; 30(24):3012-9. PubMed ID: 22802313
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, safety, tolerability and price of newly approved drugs in solid tumors.
Barnes TA; Amir E; Templeton AJ; Gomez-Garcia S; Navarro B; Seruga B; Ocana A
Cancer Treat Rev; 2017 May; 56():1-7. PubMed ID: 28437678
[TBL] [Abstract][Full Text] [Related]
5. Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses.
Ocana A; Ethier JL; Díez-González L; Corrales-Sánchez V; Srikanthan A; Gascón-Escribano MJ; Templeton AJ; Vera-Badillo F; Seruga B; Niraula S; Pandiella A; Amir E
Oncotarget; 2015 Nov; 6(37):39538-49. PubMed ID: 26446908
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials.
Funakoshi T; Latif A; Galsky MD
Cancer Treat Rev; 2014 Jun; 40(5):636-47. PubMed ID: 24629273
[TBL] [Abstract][Full Text] [Related]
8. Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation.
Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
BMC Cancer; 2019 Jan; 19(1):56. PubMed ID: 30634944
[TBL] [Abstract][Full Text] [Related]
9. Second-line systemic therapy for metastatic colorectal cancer.
Mocellin S; Baretta Z; Roqué I Figuls M; Solà I; Martin-Richard M; Hallum S; Bonfill Cosp X
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD006875. PubMed ID: 28128439
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates in multiple myeloma: a network meta-analysis.
Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
[TBL] [Abstract][Full Text] [Related]
11. The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials.
Roviello G; Bachelot T; Hudis CA; Curigliano G; Reynolds AR; Petrioli R; Generali D
Eur J Cancer; 2017 Apr; 75():245-258. PubMed ID: 28242502
[TBL] [Abstract][Full Text] [Related]
12. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
13. The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia.
Li X; Xu S; Tan Y; Chen J
Cochrane Database Syst Rev; 2015 Jun; (6):CD010432. PubMed ID: 26037486
[TBL] [Abstract][Full Text] [Related]
14. A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors: A Meta-analysis of Correlation and Differences in Effect Sizes.
Gyawali B; Hey SP; Kesselheim AS
JAMA Netw Open; 2018 Jun; 1(2):e180416. PubMed ID: 30646078
[TBL] [Abstract][Full Text] [Related]
15. Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H
Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of amrubicin-based regimen used as first-line for extensive-disease small-cell lung cancer: A meta-analysis of randomized controlled trials.
Liu CQ; Tian D; Wang N; Meng XP; Yang JD; Li HW; Zhao N; Zhao S; Liao F; Cui Y
Asia Pac J Clin Oncol; 2018 Apr; 14(2):e81-e87. PubMed ID: 29071806
[TBL] [Abstract][Full Text] [Related]
17. Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.
Landre T; Guetz GD; Chouahnia K; Fossey-Diaz V; Taleb C; Culine S
Clin Genitourin Cancer; 2019 Aug; 17(4):e806-e813. PubMed ID: 31227430
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic Therapy in Advanced Non-small-cell Lung Cancer: A Meta-analysis of Phase III Randomized Trials.
Raphael J; Chan K; Karim S; Kerbel R; Lam H; Santos KD; Saluja R; Verma S
Clin Lung Cancer; 2017 Jul; 18(4):345-353.e5. PubMed ID: 28188101
[TBL] [Abstract][Full Text] [Related]
19. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
Shepherd AR; Shepherd E; Brook NR
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
[TBL] [Abstract][Full Text] [Related]
20. Phase III trials of standard chemotherapy with or without bevacizumab for ovarian cancer: a meta-analysis.
Zhou M; Yu P; Qu X; Liu Y; Zhang J
PLoS One; 2013; 8(12):e81858. PubMed ID: 24324725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]